Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Compass Therapeutics, Inc. (CMPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2400-0.0600 (-2.61%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close2.3000
Open2.2800
Bid1.9800 x 1200
Ask2.4000 x 1000
Day's Range2.1800 - 2.3050
52 Week Range1.2500 - 4.3800
Volume87,460
Avg. Volume195,412
Market Cap226.878M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.0890
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CMPX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Compass Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

    BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place in New York City September 12 – 14, 2022. Presentation details: Date: Tuesday, September 13, 2022 Time: 2:30 PM EDT Webcast: https://journey.ct.events Virtual/Replay

  • GlobeNewswire

    Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

    BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will present at the 2022 Wedbush PacGrow Healthcare Conference that will take place virtually August 9 – 10, 2022. Date: August 9, 2022 Time: 4:05 pm ET Webcast: https://wsw.com/webcast/wedbush42/cmpx/2242880 Virtual/Replay availability: The presentation will be archived for 90 days o

  • GlobeNewswire

    Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A Phase 2 trial of CTX-009 as a monotherapy in advanced colorectal cancer (CRC) is on track to begin in Q4 2022 A fourth partial response (PR) has been reported in the ongoing Phase 1b monotherapy study of CTX-471 (CD137 agonist) in a patient with mesotheliomaA combination study of CTX-471 and PD-1 blocker is on track to initiate in Q4 2022$132.0

Advertisement
Advertisement